| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces recruitment of three additional patients in its investigator led pediatric Netherton Syndrome (NS) study as well as highly positive 9 month clinical data from the first pediatric patient in the study.
After 9 months of continued whole body application of QRX003, the subject's skin remains completely healed demonstrating the durability of ongoing daily treatment with the product. At baseline, prior to initiation of treatment with QRX003, the subject's skin had an Investigator's Global Assessment (IGA) of 4, on a scale of 0-4 where 4 is the most severe score possible. At 9 months, the IGA had materially improved to 0 and the subject's skin is completely clear. In addition, the subject's pruritus score (on a scale from 0-10, with 10 being the worst itch imaginable) changed from 5 at baseline to 0 at 9 months. The subject continues to experience zero nightly sleep disturbances without the need for any sedating medication, marking the first continuous period of uninterrupted sleep in their life. Furthermore, since being treated with QRX003, the subject has continued to have no requirement for previously necessary medications such as antibiotics, antivirals, antihistamines and glucocorticoids. No adverse events have been reported to date after 9 months of daily, whole-body treatment with QRX003.
In conjunction with the announcement of this highly positive data, Quoin is pleased to announce that it has recruited three additional pediatric subjects into this investigator led pediatric NS study. All three subjects will receive twice-daily whole-body application of QRX003, initially for a period of twelve weeks before continuing in a long-term extension protocol until regulatory approval has been obtained. Two of the subjects reside in Austria and the third lives in Ireland. Quoin believes data from these additional subjects will significantly add to the growing body of positive clinical data supporting QRX003 as a potential treatment for NS.
Quoin CEO Dr. Michael Myers, said, "We are pleased to announce these two significant milestone events for Quoin and our QRX003 NS program. First, the achievement of, and continued retention of, both fully healed skin and the complete elimination of pruritus in the first pediatric subject is a testament to the clinical benefit of QRX003 in NS. With no need for previously required medications, such as antibiotics, antivirals, antihistamines and glucocorticoids, and zero nightly sleep disturbance, treatment with QRX003 has truly been completely life transforming for this little girl. Second, we are excited to announce the recruitment of three additional NS subjects in Austria and Ireland. We believe that the clinical data from these subjects will continue to demonstrate positive clinical outcomes of QRX003 in NS without adverse events."
Posted In: QNRX
